Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-04-28FDA Approved: NAPROXEN — Supplemental Application (Acella Pharmaceuticals, LLC)
The FDA approved a supplemental application for Naproxen filed by Acella Pharmaceuticals, LLC, updating the product's approval status.
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (ScieGen Pharmaceuticals Inc)
FDA approved a supplemental application for Nabumetone from ScieGen Pharmaceuticals Inc, resulting in updated labeling and potential new ind…
-
FDA approval · 2021-04-28FDA Approved: INDOMETHACIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's supplemental application for Indomethacin, approving a generic Indomethacin product.
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Nabumetone.
-
FDA approval · 2021-04-28FDA Approved: INDOMETHACIN — Supplemental Application (XLCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Indomethacin from XLCare Pharmaceuticals Inc. This approval updates the drug's existing FDA appr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Etodolac submitted by Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2021-04-28FDA Approved: MECLOFENAMATE SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for meclofenamate sodium from Mylan Pharmaceuticals Inc.
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for etodolac from Amneal Pharmaceuticals NY LLC under ANDA 208834.
-
FDA approval · 2021-04-28FDA Approved: ETODOLAC — Supplemental Application (Chartwell RX, LLC)
The FDA has approved a supplemental application for etodolac submitted by Chartwell RX, LLC.
-
FDA approval · 2021-04-28FDA Approved: RELAFEN DS — Supplemental Application (Carwin Pharmaceutical Associates, LLC)
FDA approved a supplemental application for Relafen DS (nabumetone) submitted by Carwin Pharmaceutical Associates, LLC. Nabumetone is used t…
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Nabumetone submitted by Actavis Pharma, Inc., relating to Nabumetone's approval status.
-
FDA approval · 2021-04-28FDA Approved: IBUPROFEN — Supplemental Application (Major Pharmaceuticals)
The FDA approved Major Pharmaceuticals' ibuprofen supplemental application, finalizing regulatory changes for this product under an ANDA pro…
-
FDA approval · 2021-04-28FDA Approved: NABUMETONE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Nabumetone from Exelan Pharmaceuticals Inc. to modify an aspect of the approved product. This ac…
-
FDA approval · 2021-04-28FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
The FDA approved a supplemental application for Tolmetin Sodium from Atland Pharmaceuticals, LLC, updating an existing approval.
-
FDA approval · 2021-04-26FDA Approved: DICLOFENAC POTASSIUM — Supplemental Application (Trifluent Pharma LLC)
FDA approved a supplemental application for Diclofenac potassium from Trifluent Pharma LLC as a generic product.
-
FDA approval · 2021-04-26FDA Approved: INDOMETHACIN — Supplemental Application (XLCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Indomethacin submitted by XLCare Pharmaceuticals Inc. under ANDA 091240.
-
FDA approval · 2021-04-26FDA Approved: ETODOLAC — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Etodolac from Zydus Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis [Phase 2]
Phase IIb dose-ranging study in moderate to severe rheumatoid arthritis has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease [Phase 4]
Phase 4 study updating on adalimumab to lower cardiovascular risk in rheumatoid arthritis patients with well-controlled joint disease has co…
-
FDA approval · 2021-03-31FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Diclofenac Sodium from Actavis Pharma, Inc. under ANDA074514. The approval covers an updated for…
-
FDA approval · 2021-03-29FDA Approved: LEFLUNOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved an original-application generic for Leflunomide from Aurobindo Pharma Limited.
-
FDA approval · 2021-03-26FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diclofenac sodium (a generic NSAID).
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone [Phase 2]
Phase 2 double-blind trial evaluating duvelisib in patients with moderate to severe rheumatoid arthritis who have inadequate response to met…
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: Rheumatoid Arthritis Satisfaction Outcome Research
Clinical trial update for rheumatoid arthritis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy [Phase 3]
Phase 3 trial comparing LBAL to Humira in patients with active rheumatoid arthritis despite methotrexate therapy has completed.